Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 1;51(3):125-149.

MDMA to Treat PTSD in Adults

Dustin Latimer  1 , Michael D Stocker  1 , Kia Sayers  1 , Jackson Green  1 , Adam M Kaye  1 , Alaa Abd-Elsayed  1 , Elyse M Cornett  1 , Alan D Kaye  1 , Giustino Varrassi  1 , Omar Viswanath  1 , Ivan Urits  1
Affiliations
Review

MDMA to Treat PTSD in Adults

Dustin Latimer et al. Psychopharmacol Bull. .

Abstract

Post-traumatic stress disorder (PTSD) has become one of the most common psychiatric diagnosis in the United States specifically within the veteran population. The current treatment options for this debilitating diagnosis include trauma-focused psychotherapies along with selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI).1 MDMA has recently been shown as a novel therapeutic agent with promisingly results in the treatment of PTSD. MDMA is a psychoactive compound traditionally categorized as a psychedelic amphetamine that deemed a Schedule I controlled substance in the 1980s. Prior to its status as a controlled substance, it was used by psychotherapists for an array of psychiatric issues. In more recent times, MDMA has resurfaced as a potential therapy for PTSD and the data produced from randomized, controlled trials back the desire for MDMA to be utilized as an effective pharmacologic therapy in conjunction with psychotherapy.2.

Keywords: MAPS; MDMA; PTSD; post traumatic stress disorder; psychotherapy.

PubMed Disclaimer

References

    1. Hoskins M et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. British Journal of Psychiatry. 2015;206(2):93–100. doi: 10.1192/bjp.bp.114.148551. doi: - DOI - PubMed
    1. Sessa B. MDMA and PTSD treatment: ‘PTSD: from novel pathophysiology to innovative therapeutics,’. Neuroscience Letters. 2017;649:176–180. doi: 10.1016/j.neulet.2016.07.004. doi: - DOI - PubMed
    1. Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy Versus Pharmacotherapy For Posttraumatic Stress Disorder: systemic review and meta-analyses to determine first-line treatments. Depression and Anxiety. 2016;33(9):792–806. doi: 10.1002/da.22511. doi: - DOI - PubMed
    1. Stein DJ, Ipser JC, Seedat S, Sager C, Amos T. Pharmacotherapy for post traumatic stress disorder (PTSD) Cochrane Database Syst. Rev. 2006;2006(1):CD002795. doi: 10.1002/14651858.cd002795.pub2. doi: - DOI - PMC - PubMed
    1. Akiki TJ, Abdallah CG. Are there effective psychopharmacologic treatments for PTSD? Journal of Clinical Psychiatry. 2018;80(3):18ac12473. doi: 10.4088/JCP.18ac12473. doi: - DOI - PMC - PubMed

MeSH terms

Substances